Intended Audience:
This symposium is designed for cardiologists, program directors, PAs, NPs, prehospital care providers, pharmacists, and other healthcare providers caring for patients with acute cardiovascular disease.
Registration:
Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified symposium and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support:
Supported by an independent educational grant from The Medicines Company, Inc.
Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education
through the joint sponsorship of The University of Massachusetts Medical School
and CMEducation Resources, LLC. The University of Massachusetts Medical School
is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity
for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair
balance, independence, objectivity and scientific rigor in all activities. All
faculty participating in CME activities sponsored by the University of Massachusetts
Medical School are required to present evidence-based data, identify and reference
off-label product use and disclose all relevant financial relationships with those
supporting the activity or others whose products or services are discussed. Faculty
disclosure will be provided in the activity materials.
Faculty Disclosures:
Peter Berger, MD, FACC
Received research support from Conor (greater than $10,000) and Cardiokinetix (less than $10,000), spoken at CME approved scientific symposia supported by BMS, Sanofi-Aventis, The Medicines Company,and Lilly/Daiichi Sankyo, received honoraria from Biogen and Shering Plough (<$10,000), served as a consultant to Cordis/Johnson & Johnson and Boston Scientific (each for less than $10,000), and owns equity in Lumen, Inc. (a company that is developing an embolic protection device) (greater than $10,000).
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Honoraria or Grant/Research Support: Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Eisai, Glaxo Smith Kline, Millennium, Paringenix, PDL, Schering Plough, sanofi-aventis, The Medicines Company.
James Ferguson, MD, FACC
Grant/Research Support: Eisai Pharmaceuticals, The Medicines Company. Vitatron/Medtronic
Consulting/Honoraria: Bristol Myers-Squibb, Eisai Pharmaceuticals, GlaxoSmithKline, Prism Pharmaceuticals, sanofi-aventis, Schering-Plough, Takeda Pharnmaceuticals, The Medicines Company, Therox
Speaker’s Bureau: Bristol Myers-Squibb, sanofi-aventis, Schering-Plough
Steven V. Manoukian, MD, FACC
Grant/Research Support: The Medicines Company
Speaker’s Bureau: The Medicines Company
Sunil V. Rao, MD
Consultant: sanofi-aventis, The Medicines Company, Pfizer, Cordis
Research funding: Agency for Healthcare Research & Quality, National Institute for Aging, American College of Cardiology
Program Faculty
Peter B. Berger, MD, FACC
Associate Chief Research Officer for Clinical Studies
Geisinger Health System
Danville, Pennsylvania
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Associate Director, Cleveland Clinic Cardiovascular
Coordinating Center
Staff, Cardiac, Peripheral, and Carotid Intervention
Associate Professor of Medicine
Department of Cardiovascular Medicine
Cleveland Clinic Foundation
James Ferguson, MD, FACC
Associate Director of Cardiology Research
St. Luke’s Episcopal Hospital and Texas Heart Institute
Houston, Texas
Assistant Professor of Medicine
Baylor College of Medicine
Assistant Clinical Professor of Medicine
University of Texas Health Sciences Center
Co-Editor, Acute Coronary Syndromes
Steven V. Manoukian, MD, FACC
Director, Interventional Cardiology
Emory-Crawford Long Hospital
Emory University School of Medicine
President, American Heart Association, Atlanta Division
Atlanta, Georgia
Sunil V. Rao, MD
Assistant Professor of Medicine
Duke University Medical Center
Director, Cardiac Catheterization Laboratories
Durham VA Medical Center
Durham, NC
Educational Objectives:
• As a result of this session, cardiologists will be able to assess and implement optimal antithrombotic strategies for patients with acute coronary syndromes.
• As a result of this session, attendees will understand impact of specific pharmacologic agents on outcomes, including ischemic endpoints, bleeding, and mortality for patients with ACS.
• As a result of this session, attendees are able to discuss the impact that new trials are likely to have on future management of patients with ACS.
• As a result of this session, cardiologists will learn to apply AHA/ACC, ACCP, and other national guidelines in order to optimize therapy ACS.
Copyright (c) 2006 All rights reserved including
